SEHK:399

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Innovative Pharmaceutical Biotech

Executive Summary

Innovative Pharmaceutical Biotech Limited, an investment holding company, provides genetic testing services in the People’s Republic of China and Hong Kong.


Snowflake Analysis

Weak fundamentals or lack of information.

Share Price & News

How has Innovative Pharmaceutical Biotech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 399 has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.5%

399

-0.6%

HK Trade Distributors

0.7%

HK Market


1 Year Return

-30.9%

399

-26.3%

HK Trade Distributors

0.4%

HK Market

Return vs Industry: 399 underperformed the Hong Kong Trade Distributors industry which returned -26.3% over the past year.

Return vs Market: 399 underperformed the Hong Kong Market which returned 0.4% over the past year.


Shareholder returns

399IndustryMarket
7 Day-4.5%-0.6%0.7%
30 Day-2.5%-0.3%-1.0%
90 Day-9.6%-1.1%9.6%
1 Year-30.9%-30.9%-23.9%-26.3%4.5%0.4%
3 Year-50.0%-50.0%-46.0%-49.8%0.2%-10.6%
5 Year-71.0%-71.0%-62.4%-67.3%9.9%-8.5%

Price Volatility Vs. Market

How volatile is Innovative Pharmaceutical Biotech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Innovative Pharmaceutical Biotech undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Innovative Pharmaceutical Biotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Innovative Pharmaceutical Biotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of 399's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don't know where to start, we recommend reading through Innovative Pharmaceutical Biotech regulatory filings.
  • Explore potentially undervalued companies in the Capital Goods industry.

Future Growth

How is Innovative Pharmaceutical Biotech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.8%

Forecasted Capital Goods industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Innovative Pharmaceutical Biotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of 399’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Innovative Pharmaceutical Biotech competitive advantages and company strategy can generally be found in its financial reports archived here.
  • Explore growth companies in the Capital Goods industry.

Past Performance

How has Innovative Pharmaceutical Biotech performed over the past 5 years?

5.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 399 is currently unprofitable.

Growing Profit Margin: 399 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 399 is unprofitable, but has reduced losses over the past 5 years at a rate of 5.6% per year.

Accelerating Growth: Unable to compare 399's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 399 is unprofitable, making it difficult to compare its past year earnings growth to the Trade Distributors industry (0.9%).


Return on Equity

High ROE: 399 has a negative Return on Equity (-39.18%), as it is currently unprofitable.


Next Steps

Financial Health

How is Innovative Pharmaceutical Biotech's financial position?


Financial Position Analysis

Short Term Liabilities: 399's short term assets (HK$42.2M) do not cover its short term liabilities (HK$70.5M).

Long Term Liabilities: 399's short term assets (HK$42.2M) do not cover its long term liabilities (HK$780.6M).


Debt to Equity History and Analysis

Debt Level: 399's debt to equity ratio (146.6%) is considered high.

Reducing Debt: 399's debt to equity ratio has increased from 26.3% to 146.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 399 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 399 has less than a year of cash runway if free cash flow continues to grow at historical rates of 17.5% each year.


Next Steps

Dividend

What is Innovative Pharmaceutical Biotech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 399's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 399's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 399's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 399's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 399's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

  • Explore strong dividend paying companies in the Capital Goods industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

7.3yrs

Average management tenure


CEO

Innovative Pharmaceutical Biotech has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Rong Tang
Executive Director5.92yrsHK$548.00k0.027%
HK$ 92.7k
Yuan Xing Gao
Executive Director4.58yrsHK$1.38mno data
He Huang
Executive Director3.58yrsHK$668.00kno data
Yumin Mao
Honorary Chairman & Chief Scientific Adviser9.92yrsno data24.81%
HK$ 85.0m
Hon Yin Poon
Financial Controller & Company Secretary7.25yrsno datano data
Qi Dong
Sales Head of the Groupno datano datano data
Wei Yu
Joint Chairman to the Department of Innovation & Strategic Development and Advisorno datano datano data
Jie Gu
Adviser and Joint Chairman to the Department of Innovation & Strategic Development4.67yrsno datano data
Yi Xie
Chief Executive of United Gane Holdings Limitedno datano datano data
Dong Hui
General Manager of the Group and Director of CJVno datano datano data

7.3yrs

Average Tenure

56yo

Average Age

Experienced Management: 399's management team is seasoned and experienced (7.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Rong Tang
Executive Director5.92yrsHK$548.00k0.027%
HK$ 92.7k
Yuan Xing Gao
Executive Director4.58yrsHK$1.38mno data
He Huang
Executive Director3.58yrsHK$668.00kno data
Yumin Mao
Honorary Chairman & Chief Scientific Adviser9.92yrsno data24.81%
HK$ 85.0m
Dong Hui
General Manager of the Group and Director of CJVno datano datano data
Chung Lau
Director of CJVno datano datano data
Weijun Chen
Independent Non-Executive Director10.75yrsHK$80.00kno data
Nian Jiang
Chairman9.17yrsHK$60.00kno data
Zhihong Zhang
Independent Non-Executive Director9.17yrsHK$60.00kno data
Yanmin Wu
Non-Executive Director9.17yrsHK$152.00kno data
Rongliang Wang
Independent Non-Executive Director9.17yrsHK$60.00kno data
Yan Xiao
Non-Executive Director8.25yrsHK$60.00kno data

9.2yrs

Average Tenure

60yo

Average Age

Experienced Board: 399's board of directors are considered experienced (9.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Innovative Pharmaceutical Biotech Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Innovative Pharmaceutical Biotech Limited
  • Ticker: 399
  • Exchange: SEHK
  • Founded:
  • Industry: Trading Companies and Distributors
  • Sector: Capital Goods
  • Market Cap: HK$342.621m
  • Shares outstanding: 1.46b
  • Website: https://www.ipb.asia

Number of Employees


Location

  • Innovative Pharmaceutical Biotech Limited
  • West Tower Shun Tak Centre
  • Unit No. 2111
  • Sheung Wan
  • Hong Kong

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
399SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDAug 2000
FRHNDB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2000

Biography

Innovative Pharmaceutical Biotech Limited, an investment holding company, provides genetic testing services in the People’s Republic of China and Hong Kong. The company also engages in the trading of beaut ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/03 12:47
End of Day Share Price2020/08/03 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.